Hyaluronic Acid

Hyaluronic acid (also called hyaluronan) is a naturally occurring glycosaminoglycan — a long, unbranched sugar polymer — not a peptide or protein. It is found throughout the body, most abundantly in skin, connective tissue, and the synovial fluid of joints, where its defining property is the ability to bind and hold large volumes of water.

Because of this water-binding capacity, hyaluronic acid is widely used in cosmetic skincare formulations, in injectable dermal fillers, and in intra-articular preparations studied for joint comfort. Its behavior and regulatory status differ substantially depending on whether it is applied topically, injected aesthetically, or administered into a joint.

Hyaluronic acid does not act as a signaling peptide; its effects derive from its physical and structural chemistry. High-level themes include:

• Binding many times its own weight in water, contributing to tissue hydration and volume
• Serving as a structural component of the extracellular matrix that supports skin and connective tissue
• Contributing to the viscosity and lubricating properties of synovial fluid in joints

The molecular weight and cross-linking of a given preparation strongly influence how it behaves — for example, how long an injected filler persists or how a topical product sits on the skin surface.

Hyaluronic acid appears across a range of consumer and clinical contexts. Topically, it is a common humectant in moisturizers and serums. As an injectable, cross-linked forms are used in professionally administered dermal fillers for soft-tissue augmentation, and certain intra-articular preparations have been studied and used for joint-related discomfort.

Regulatory treatment varies by use: cosmetic topical products, aesthetic injectables, and medical-device or drug-classified joint injections are governed by different frameworks. Injectable and aesthetic applications are professional procedures and should be performed by qualified practitioners.

Because hyaluronic acid is a structural glycosaminoglycan used for hydration, aesthetics, and joint applications rather than performance enhancement, it does not fall within the categories WADA restricts. Athletes should nonetheless confirm the status of any specific product and its full ingredient list with their governing body, and note that some injection procedures can carry separate declaration or method-related considerations.

Used topically, hyaluronic acid is considered well tolerated by most people, with occasional mild irritation. Injectable aesthetic use can be associated with injection-site reactions such as redness, swelling, bruising, or lumps, and rare but more serious vascular complications, which is why professional administration matters.

Intra-articular use may be associated with transient local reactions. As with any procedure, product quality, sterile technique, and individual risk factors are important, and high-level summaries cannot substitute for professional evaluation.

Hyaluronic acid is not dosed like a systemic drug; the relevant considerations are formulation-specific rather than a single milligram amount. Conceptually, factors that shape how a preparation is used include:

• Route and setting — topical application versus professionally administered injection
• Molecular weight and degree of cross-linking, which affect persistence and texture
• Concentration within a given cosmetic or medical formulation

These are conceptual factors that formulators and clinicians weigh; this educational overview does not provide specific amounts, schedules, or protocols and does not constitute medical advice.

With hyaluronic acid, "formulation" mostly means two variables: chain length and cross-linking. Both change the material's behaviour more than any additive does.

Molecular weight. HA is conventionally split into low-molecular-weight (roughly 6–200 kDa), medium (0.2–1.0 MDa), and high (above 1 MDa), and a native chain can run to 10,000 or more repeating units — around 4 million daltons (Iaconisi et al., Int J Mol Sci 2023). Cosmetic marketing that lists "low-molecular-weight HA" is pointing at this axis, on the argument that shorter chains behave differently at the skin surface.

Cross-linking. Injectable fillers are HA chains chemically tethered to each other so the gel resists enzymatic breakdown and holds volume for months rather than hours. Uncross-linked HA in a serum has no such persistence — the two products share a molecule and almost nothing else.

Source. Historically HA was extracted from rooster combs, umbilical cord, and bovine vitreous. Industrial production has largely moved to bacterial fermentation using engineered GRAS organisms, which sidesteps both the extraction cost and the animal-protein contamination question. This is not trivia: FDA advises allergy testing before using fillers made with certain animal-derived materials, rooster comb among them (FDA, dermal fillers).

Route determines the regulatory category. A topical serum is a cosmetic. An injectable filler is a medical device implant approved for adults 22 and over. An intra-articular preparation is regulated separately again. The same molecule crosses three frameworks depending only on where it is put.

Research on hyaluronic acid spans dermatology, aesthetics, and orthopedics. Topical hydration effects and the volumizing behavior of injectable fillers are reasonably well characterized, while evidence for intra-articular use in joint conditions has been more mixed across studies and guidelines.

Because outcomes depend heavily on formulation, molecular weight, and the specific application, findings from one context do not automatically transfer to another. High-level overviews are not a substitute for critical appraisal of the primary literature.

For deeper dives on this ingredient, see:

• Hyaluronic acid benefits and areas of interest
• Hyaluronic acid side effects and safety context
• Hyaluronic acid usage concepts (educational)
• Hyaluronic acid research and evidence overview

Is hyaluronic acid a peptide? No — it is a sugar polymer. Hyaluronan is a glycosaminoglycan built from a repeating disaccharide of glucuronic acid and N-acetylglucosamine, joined by alternating β-1,3 and β-1,4 glycosidic bonds (Iaconisi et al., Int J Mol Sci 2023). There are no amino acids and no peptide bonds anywhere in it. It sits in peptide catalogs because it shares shelf space with cosmetic injectables, not because it shares chemistry with them.

Does it matter whether HA is applied, injected, or swallowed? Enormously — these are three different interventions. Topically, HA is a humectant sitting at the skin surface. Injected as a cross-linked gel, it is a space-filling implant. Injected into a joint, it is meant to alter synovial fluid viscosity. Swallowed, it enters the digestive tract first, and the trials of oral HA for skin or joint outcomes are small, short, and largely industry-funded rather than the kind of large placebo-controlled evidence the injectable routes have accumulated. Findings from one route say very little about another.

What is the difference between a filler and a viscosupplement? Cross-linking, placement, and purpose. Fillers are cross-linked gels placed in soft tissue for volume — FDA approves them as medical device implants for adults 22 and older, for facial wrinkles and folds and for augmentation of lips, cheeks, chin, and the back of the hand (FDA, dermal fillers). Viscosupplements are injected into a joint space with the goal of restoring the lubricating properties of synovial fluid. Same polymer, non-interchangeable products.

Do HA injections work for knee osteoarthritis? The largest synthesis says the effect is real but too small to feel. Pooling 24 large placebo-controlled trials in 8,997 participants, viscosupplementation reduced pain by a standardised mean difference of −0.08 — about 2.0 mm on a 100 mm visual analogue scale — against a minimal clinically important difference of roughly 9 mm. In 15 trials with 6,462 participants, serious adverse events were more common with viscosupplementation than placebo (3.7% vs 2.5%, relative risk 1.49) (Pereira et al., BMJ 2022). The authors' own conclusion was that the evidence is now strong and conclusive that the benefit falls below the minimal clinically important difference — negligible benefit alongside a measurable harm signal.

What is the most serious risk of HA fillers? Unintentional injection into a blood vessel. FDA describes this as the most concerning risk of dermal fillers: it blocks blood supply to tissue, and the resulting complications can be serious and permanent, including necrosis, vision abnormalities including blindness, and stroke. Because HA is enzymatically degradable, hyaluronidase is the standard intervention — consensus guidance recommends a minimum of 200 to 300 units injected across the affected area, repeated daily until blood flow is restored, with doses up to 1,500 units sometimes needed (Signorini et al., Plast Reconstr Surg 2016). Non-HA and permanent fillers have no equivalent antidote, which is a real argument in HA's favour.

Is hyaluronic acid vegan? Usually now, historically not. HA was originally extracted from rooster combs, umbilical cord, and bovine vitreous humour; most industrial production has shifted to bacterial fermentation with engineered generally-recognised-as-safe organisms. Products vary, and FDA still advises allergy testing before fillers made with animal-derived materials.

Is hyaluronic acid banned in sport? No. It is not on the WADA Prohibited List and is not a hormone, growth factor, or metabolic modulator. Intra-articular injections are not a prohibited method either — the M2.2 restriction covers intravenous infusions and injections exceeding 100 mL per 12 hours, a volume no joint injection approaches.